Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Accumulated Expenses: 2019-2024

Historic Accumulated Expenses for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $34.9 million.

  • Kymera Therapeutics' Accumulated Expenses rose 7.95% to $28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.6 million, marking a year-over-year increase of 7.95%. This contributed to the annual value of $34.9 million for FY2024, which is 2.96% up from last year.
  • As of FY2024, Kymera Therapeutics' Accumulated Expenses stood at $34.9 million, which was up 2.96% from $33.9 million recorded in FY2023.
  • Over the past 5 years, Kymera Therapeutics' Accumulated Expenses peaked at $34.9 million during FY2024, and registered a low of $10.3 million during FY2020.
  • For the 3-year period, Kymera Therapeutics' Accumulated Expenses averaged around $32.1 million, with its median value being $33.9 million (2023).
  • Data for Kymera Therapeutics' Accumulated Expenses shows a peak YoY surged of 126.14% (in 2020) over the last 5 years.
  • Over the past 5 years, Kymera Therapeutics' Accumulated Expenses (Yearly) stood at $10.3 million in 2020, then soared by 122.37% to $23.0 million in 2021, then rose by 19.72% to $27.5 million in 2022, then grew by 23.13% to $33.9 million in 2023, then rose by 2.96% to $34.9 million in 2024.